Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rho, Seung Bae | - |
dc.contributor.author | Byun, Hyun-Jung | - |
dc.contributor.author | Park, Sang-Yoon | - |
dc.contributor.author | Chun, Taehoon | - |
dc.date.accessioned | 2021-09-08T21:01:05Z | - |
dc.date.available | 2021-09-08T21:01:05Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2009-01 | - |
dc.identifier.issn | 0141-5492 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120799 | - |
dc.description.abstract | Cysteine-rich 61 (CYR61), a member of the connective tissue factor CCN (Cyr61, CTGF, Nov) family, facilitates angiogenesis by interacting with integrins. Recent observations have indicated that CYR61 also rescues cells from anti-cancer drug-mediated apoptosis but the detailed mechanism underlying the role of CYR61 during apoptosis has not been identified. To better understand the role of CYR61 during cisplatin-induced apoptosis in tumor cells, we overexpressed or inhibited CYR61 expression in human cervical cancer cells (HeLa cells) and measured cisplatin-mediated apoptosis. The results from these experiments clearly demonstrate that CYR61 prevents cisplatin-induced apoptosis by inhibiting caspase-3 activity in HeLa cells. Therefore, CYR61 may be a useful therapeutic target for cisplatin-resistant tumors. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | IMMEDIATE-EARLY GENE | - |
dc.subject | HUMAN BREAST-CANCER | - |
dc.subject | ANGIOGENIC FACTOR | - |
dc.subject | PROLIFERATION | - |
dc.subject | EXPRESSION | - |
dc.subject | PRODUCT | - |
dc.subject | GROWTH | - |
dc.subject | LINES | - |
dc.subject | CCN1 | - |
dc.title | Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chun, Taehoon | - |
dc.identifier.doi | 10.1007/s10529-008-9845-8 | - |
dc.identifier.scopusid | 2-s2.0-56649089697 | - |
dc.identifier.wosid | 000262966200003 | - |
dc.identifier.bibliographicCitation | BIOTECHNOLOGY LETTERS, v.31, no.1, pp.23 - 28 | - |
dc.relation.isPartOf | BIOTECHNOLOGY LETTERS | - |
dc.citation.title | BIOTECHNOLOGY LETTERS | - |
dc.citation.volume | 31 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 23 | - |
dc.citation.endPage | 28 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.subject.keywordPlus | IMMEDIATE-EARLY GENE | - |
dc.subject.keywordPlus | HUMAN BREAST-CANCER | - |
dc.subject.keywordPlus | ANGIOGENIC FACTOR | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PRODUCT | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | LINES | - |
dc.subject.keywordPlus | CCN1 | - |
dc.subject.keywordAuthor | Anti-cancer agent | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Caspase | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Cysteine-rich 61 (CYR61) | - |
dc.subject.keywordAuthor | Ovarian carcinoma cell | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.